vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and OneStream, Inc. (OS). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $163.7M, roughly 1.0× OneStream, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 23.6%). Over the past eight quarters, OneStream, Inc.'s revenue compounded faster (21.8% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Blue Stream provides cable television, cable telephone, DVR, and up to 1 GIG Internet speed broadband services to customers in the Florida communities of Coral Springs and Weston.
ESPR vs OS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $163.7M |
| Net Profit | — | $999.0K |
| Gross Margin | — | 69.8% |
| Operating Margin | 50.6% | -3.2% |
| Net Margin | — | 0.6% |
| Revenue YoY | 143.7% | 23.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $163.7M | ||
| Q3 25 | $87.3M | $154.3M | ||
| Q2 25 | $82.4M | $147.6M | ||
| Q1 25 | $65.0M | $136.3M | ||
| Q4 24 | $69.1M | $132.5M | ||
| Q3 24 | $51.6M | $129.1M | ||
| Q2 24 | $73.8M | $117.5M | ||
| Q1 24 | $137.7M | $110.3M |
| Q4 25 | — | $999.0K | ||
| Q3 25 | $-31.3M | $-8.8M | ||
| Q2 25 | $-12.7M | $-18.4M | ||
| Q1 25 | $-40.5M | $-24.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-171.9M | ||
| Q2 24 | $-61.9M | $-7.8M | ||
| Q1 24 | $61.0M | $-5.0M |
| Q4 25 | — | 69.8% | ||
| Q3 25 | — | 68.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 68.0% | ||
| Q4 24 | — | 66.8% | ||
| Q3 24 | — | 50.1% | ||
| Q2 24 | — | 68.5% | ||
| Q1 24 | — | 69.1% |
| Q4 25 | 50.6% | -3.2% | ||
| Q3 25 | -11.4% | -11.3% | ||
| Q2 25 | 8.6% | -21.8% | ||
| Q1 25 | -34.0% | -29.3% | ||
| Q4 24 | -6.4% | -35.8% | ||
| Q3 24 | -31.0% | -197.6% | ||
| Q2 24 | 3.5% | -9.8% | ||
| Q1 24 | 52.5% | -4.9% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | -35.9% | -5.7% | ||
| Q2 25 | -15.4% | -12.5% | ||
| Q1 25 | -62.2% | -17.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -133.1% | ||
| Q2 24 | -83.9% | -6.7% | ||
| Q1 24 | 44.3% | -4.5% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | $-1.06 | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $693.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $504.7M |
| Total Assets | $465.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $693.6M | ||
| Q3 25 | $92.4M | $653.9M | ||
| Q2 25 | $86.1M | $652.1M | ||
| Q1 25 | $114.6M | $593.9M | ||
| Q4 24 | $144.8M | $544.2M | ||
| Q3 24 | $144.7M | $495.5M | ||
| Q2 24 | $189.3M | $140.5M | ||
| Q1 24 | $226.6M | — |
| Q4 25 | $-302.0M | $504.7M | ||
| Q3 25 | $-451.4M | $472.1M | ||
| Q2 25 | $-433.5M | $458.2M | ||
| Q1 25 | $-426.2M | $412.9M | ||
| Q4 24 | $-388.7M | $386.2M | ||
| Q3 24 | $-370.2M | $458.2M | ||
| Q2 24 | $-344.2M | $97.5M | ||
| Q1 24 | $-294.3M | $102.5M |
| Q4 25 | $465.9M | $1.0B | ||
| Q3 25 | $364.0M | $949.4M | ||
| Q2 25 | $347.1M | $910.5M | ||
| Q1 25 | $324.0M | $867.3M | ||
| Q4 24 | $343.8M | $823.2M | ||
| Q3 24 | $314.1M | $750.1M | ||
| Q2 24 | $352.3M | $379.7M | ||
| Q1 24 | $373.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $25.8M |
| Free Cash FlowOCF − Capex | — | $25.6M |
| FCF MarginFCF / Revenue | — | 15.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 25.79× |
| TTM Free Cash FlowTrailing 4 quarters | — | $95.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $25.8M | ||
| Q3 25 | $-4.3M | $5.0M | ||
| Q2 25 | $-31.4M | $29.7M | ||
| Q1 25 | $-22.6M | $36.2M | ||
| Q4 24 | $-35.0M | — | ||
| Q3 24 | $-35.3M | $2.4M | ||
| Q2 24 | $-7.2M | $8.1M | ||
| Q1 24 | $53.8M | $25.5M |
| Q4 25 | — | $25.6M | ||
| Q3 25 | — | $4.8M | ||
| Q2 25 | — | $29.4M | ||
| Q1 25 | — | $35.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | $1.3M | ||
| Q2 24 | $-7.3M | $7.7M | ||
| Q1 24 | $53.8M | $24.9M |
| Q4 25 | — | 15.7% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | — | 19.9% | ||
| Q1 25 | — | 26.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | 1.0% | ||
| Q2 24 | -9.9% | 6.6% | ||
| Q1 24 | 39.0% | 22.5% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | 0.8% | ||
| Q2 24 | 0.1% | 0.3% | ||
| Q1 24 | 0.1% | 0.6% |
| Q4 25 | — | 25.79× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
